Abstract: The present invention concerns carrier particles suitable for use in dry powder formulations for inhalation. The invention also relates to processes for their preparation by spray-congealing.
Type:
Application
Filed:
July 24, 2019
Publication date:
September 23, 2021
Applicant:
CHIESI FARMACEUTICI S.p.A.
Inventors:
Tomaso GUIDI, Amrit PAUDEL, Sarah Elizabeth ZELLNITZ, Joana Filipa Fernandes TEIXEIRA PINTO
Abstract: The invention relates to compounds of formula I inhibiting Rho Kinase that are bicyclic dihydropyrimidine-carboxamide derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
Type:
Application
Filed:
July 12, 2019
Publication date:
September 16, 2021
Applicant:
CHIESI FARMACEUTICI S.p.A.
Inventors:
Alessandro ACCETTA, Fabio RANCATI, Anna Maria CAPELLI, David Edward CLARK, Patrizia TISSELLI, Christine EDWARDS, Amaud Jean Francois Auguste CHEGUILLAUME, Gurdip BHALAY
Abstract: Pharmaceutical formulations comprising clevidipine in an oil-in-water formulation that is resistant to microbial growth and stable against the formation of impurities.
Type:
Grant
Filed:
February 6, 2014
Date of Patent:
August 31, 2021
Assignee:
CHIESI FARMACEUTICI S.P.A.
Inventors:
Rajeshwar Motheram, Gregory Charles Williams
Abstract: The invention relates to compounds of formula I inhibiting Rho Kinase that are azaindole derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
Type:
Application
Filed:
June 11, 2019
Publication date:
August 19, 2021
Applicant:
CHIESI FARMACEUTICI S.p.A.
Inventors:
Alessandro ACCETTA, Fabio RANCATI, David Edward CLARK, Christine EDWARDS
Abstract: Administering a pulmonary surfactant and a corticosteroid in a low dose is effective for the prophylaxis of bronchopulmonary dysplasia (BPD) in preterm neonates.
Type:
Application
Filed:
March 17, 2021
Publication date:
July 22, 2021
Applicants:
CHIESI FARMACEUTICI S.p.A., CHILDREN'S HOSPITAL MEDICAL CENTER
Inventors:
Alan JOBE, Augusto SCHMIDT, Noah HILLMAN, Matthew KEMP
Abstract: Drug delivery devices that include a microphone and processing circuitry that can detect operating events, such as peak inspiratory flow (PIF) and Breath Actuated Mechanism (BAM) in dry powder inhalers can be used to improve clinical trials by providing information about the way in which the inhalers under test are being used.
Type:
Grant
Filed:
November 1, 2013
Date of Patent:
July 6, 2021
Assignee:
CHIESI FARMACEUTICI S.p.A.
Inventors:
Mark Parry-Billings, Mario Scuri, Maria Chiara Taverna
Abstract: Dry powder formulations for inhalation containing a combination of an anticholinergic, a long-acting beta2-adrenoceptor agonist, and a corticosteroid are useful for the prevention and/or treatment of an inflammatory and/or obstructive airways disease.
Abstract: Crystalline microparticles consisting of a phenylalkylamino beta2-adrenergic agonist coated with a C12-C20 fatty acid are useful for the preparation of pharmaceutical aerosol formulations in form of suspension in a liquefied propellant gas or powder formulations.
Type:
Grant
Filed:
May 12, 2016
Date of Patent:
May 4, 2021
Assignee:
Chiesi Farmaceutici S.p.A.
Inventors:
Gaetano Brambilla, Paolo Colombo, Francesca Buttini, Michele Miozzi
Abstract: Dry powder formulations for inhalation containing a combination of an anticholinergic, a long-acting beta2-adrenoceptor agonist, and a corticosteroid are useful for the prevention and/or treatment of an inflammatory and/or obstructive airways disease.
Abstract: Dry powder formulations for inhalation comprising a combination of an anti-cholinergic, a long-acting beta2-adrenoceptor agonist, and, optionally, an inhaled corticosteroid are useful for the prevention and/or treatment of an inflammatory and/or obstructive airways disease.
Abstract: Bicyclic dihydropyrimidine-carboxamide compounds of formula I described herein inhibit Rho Kinase and may be used for the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
Type:
Grant
Filed:
October 18, 2019
Date of Patent:
March 23, 2021
Assignee:
CHIESI FARMACEUTICI S.P.A.
Inventors:
Alessandro Accetta, Fabio Rancati, Anna Maria Capelli, David Edward Clark, Patrizia Tisselli, Christine Edwards, Gurdip Bhalay, Arnaud Jean Francois Auguste Cheguillaume
Abstract: The method and system according to preferred embodiments of the present invention allows an effective delivery of aerosolized medicament (e.g., a surfactant) to the patient's lungs. According to a preferred embodiment, the method of the present invention provides an efficient delivery of the aerosol medicament (possibly breath synchronized). A glass vial in which medicaments are usually stored and shipped is used directly as a component of the system. Its function in the system is that of an intermittently pressurized chamber that can inject the surfactant into the catheter of the atomizer device. According to a preferred embodiment the delivery can be done in phase with the beginning of each inspiration. The main elements of the system are: a source of compressed gas, the already mentioned medicament vial, a catheter, and optionally means to detect the breathing pattern and a control unit.
Abstract: The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.
Abstract: The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.
Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.
Abstract: The present invention relates to the use of agents, which are 1-phenyl-2-pyridinyl alkyl alcohol derivatives, for the prevention and/or treatment of cystic fibrosis in a subject, wherein the subject is characterized by at least one mutation in the gene encoding the CFTR protein, wherein the at least one mutation is causative for incorrect folding and/or processing of the CFTR protein. By the use of the compound according to the present invention, cystic fibrosis in the subject may be prevented or treated. The agent to be used according to the present invention has the capacity to restore the presence of the mutant CFTR protein at the cell surface, and thus act as CFTR correctors. The agent to be used according to the present invention may be administered to a subject in need thereof alone or in combination therapy with other agents, and is suitably administered by inhalation.
Abstract: A pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa as active ingredients and one or more excipients. Once dispersed in an aqueous medium, melevodopa is completely dissolved, and carbidopa is present as nanoparticles.
Type:
Application
Filed:
February 21, 2019
Publication date:
January 14, 2021
Applicant:
CHIESI FARMACEUTICI S.p.A.
Inventors:
Ricardo INACIO, Mark SAUNDERS, Bhanvi MEHTA, Kathrin MUEHLHOELZL-ODOERFER, Isabel Sole FONT, Grazia CAIVANO
Abstract: Stable aerosol solution formulations comprising glycopyrronium bromide are useful for administration to patients with COPD and other respiratory conditions.
Abstract: Methods for controlling, maintaining, or reducing blood pressure, and/or for treating, preventing, or alleviating symptoms such as dyspnea, in a patient suffering from or susceptible to acute heart failure. The methods involve the administration of an effective amount of a pharmaceutical composition comprising a short acting dihydropyridine compound such as clevidipine. The pharmaceutical composition may be administered at an initial dose, and if blood pressure is not controlled or maintained within a target blood pressure range or reduced to within a target blood pressure range, the initial dose may be titrated to achieve a blood pressure within the target blood pressure range. The patient may have a systolic blood pressure of about 120 mmHg or above.
Type:
Grant
Filed:
October 26, 2013
Date of Patent:
January 5, 2021
Assignee:
Chiesi Farmaceutici S.p.A.
Inventors:
Edward C. Spindler, Jr., Loretta M. Itri, Gregory Williams, Ming-yi Hu